[New drugs for metastatic kidney cancer]

Area of Science:

• Oncology
• Translational Medicine
• Pharmacology

Background:

• Systemic therapy for metastatic kidney cancer (mRCC) has historically relied on cytokines.
• Recent advancements stem from a deeper understanding of mRCC histological subtypes, genetic alterations, and critical signaling pathways involved in tumor progression.
• Identifying these pathways provides novel targets for therapeutic intervention.

Purpose of the Study:

• To review novel systemic drugs for metastatic kidney cancer treatment.
• To discuss drugs targeting the VEGF, EGFR, and mTOR signaling pathways.
• To outline current therapeutic decision-making factors in mRCC.

Main Methods:

• Review of recent clinical trials (Phase I, II, and III) for systemic therapies in mRCC.
• Analysis of drugs targeting specific molecular pathways (VEGF, EGFR, mTOR).
• Discussion of factors influencing current treatment strategies.

Main Results:

• Four new drugs have completed Phase III trials and are approved or nearing approval for mRCC.
• Numerous other agents targeting key signaling pathways are under investigation in early-phase trials.
• Therapy decisions are increasingly influenced by prognostic groups, line of therapy, combination strategies, and histological subtypes.

Conclusions:

• The treatment landscape for mRCC has been significantly transformed by targeted therapies.
• New drugs predominantly interact with VEGF, EGFR, and mTOR signaling pathways, offering new hope.
• Personalized treatment approaches considering prognostic factors, histology, and treatment lines are crucial for optimal outcomes in mRCC.